A c-MET receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) used for the treatment of advanced kidney cancer. Cabozantinib works by interfering with the growth of cancer cells and blocking the development of a new blood supply (angiogenesis) to the tumour, thereby starving the tumour of nutrients and oxygen needed to grow. Cabozantinib is a type of angiogenesis inhibitor. Cabozantinib is the chemical (or generic) name of the drug, while Cabometyx is the brand (or trade) name under which the drug is licensed and sold.

« Back to Glossary Index